Back to search results

Observing Food Behavior Changes with GLP-1 Medication

This study aims to understand how GLP-1 medications, used for weight loss, change a person's relationship with food. Researchers want to see how these medications affect the types and amounts of food you choose. You might be able to join if you are an adult (18 or older) with overweight or obesity (BMI over 25) and are either about to start GLP-1 medication or have just started it within the last two weeks. The study will look at changes in the total weight, calories, and energy density of food you select in a virtual reality (VR) buffet over three months. This is an observational study, meaning researchers will watch for changes rather than giving you a new treatment. The study plans to enroll 25 participants, but its current status is unclear.

Study design
This is an observational study with 25 planned participants. It is not specified if there are different phases.
What's involved
You would have one visit before starting GLP-1 medication and another visit three months after starting it. No other changes are administered between visits.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for three months after starting GLP-1 medication to observe changes in food selection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06843512

Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication

Recruiting
Not specifiedAges 18+Observational
Penn State University
~25 participants
Updated 2025-09-10 on ClinicalTrials.gov
What's tested:GLP-1 Medication Initiation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 Months
Measured over Baseline and 3 months
+3 more outcomes measured

Conditions

Weight Loss
Food Selection

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Travis Masterson · PRINCIPAL_INVESTIGATOR · The Pennsylvania State University

Who to contact

Christina M Blackmon
[email protected]
425-499-8049
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults (18+) with overweight or obesity (BMI \>25 kg/m2)
Not currently taking an incretin-based medication at baseline
Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
Fluent in English

Exclusion

Adults (18+) without overweight or obesity
\<18 years of age at time of testing
Adults not taking a GLP-1 Medication
Adults taking a compound GLP-1
Adults on GLP-1 medication for longer than 2 weeks at baseline
Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
Not fluent in English

What this trial measures

  • Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 MonthsBaseline and 3 months
  • Change from Baseline in Total Calories of Food Selected in the VR Buffet at 3 MonthsBaseline and 3 months
  • Change from Baseline in Energy Density of Food Selected in the VR Buffet at 3 MonthsBaseline and 3 months
  • Change from Baseline in Variety of Food Selected in the VR Buffet at 3 MonthsBaseline and 3 months